In this talk, discover how Lonza is advancing the GS Gene Expression System® platform to help meet the growing demands of modern biotherapeutic development. The GS Ori-Go® vector system represents the latest evolution in expression vector technology, leveraging an innovative method of glutamine synthetase regulation and enhanced expression control to drive higher productivity and a streamlined cell line development workflow that can accelerate timelines to IND, reduce risk, and help bring promising therapies to the clinic faster.
You may also be interested in:
Expression Technologies
Bispecific Antibody
GS Ori-Go® Vectors
Cell Line Development
Author(s):
Peter O'Callaghan, Ph.D.
Head of Expression System Sciences
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.
Latest briefing from the Knowledge Center
White paper
Accelerate the Timeline from Gene to Lead Clone with New GS Ori-Go® Vectors
Drug developers face tremendous pressure to increase efficiency and productivity, and reduce...
Peer-reviewed publication
Next‐Generation Glutamine Synthetase Expression Vector for Therapeutic Protein Manufacturing Using...
The glutamine synthetase expression system is widely used for therapeutic protein biomanufacturing...
Webinar (on-demand)
Development of Fit-For-Purpose In Vivo LVV Manufacturing Process
The transition of lentiviral vectors (LVVs) from an ex vivo manufacturing tool to a directly...
Webinar (on-demand)
One Partner for Your Entire ADC Journey
The path from ADC development to commercial manufacturing is becoming increasingly complex,...
Webinar (on-demand)
IND in as Little as 6 Months: Now Beyond mAbs
As pressure to reach critical development milestones faster continues to grow, sponsors are seeking...
Article
Viral Vector Production: How CDMOs Influence Late-Stage Development Success
Viral cell and gene therapies (CGT) have transformed modern medicine by offering durable, and in...
R&D Blog post
From Short Reads to Deeper Insight: Advancing Genetic Characterization in Biologics
DNA sequencing has transformed healthcare by helping scientists identify the genetic causes of many...
White paper
Overcoming ADC Manufacturing Challenges
Antibody-drug conjugates (ADCs) are among the most promising and complex modalities in oncology...
White paper
Beyond Capacity: Securing Reliable Supply at Commercial Scale
Securing commercial supply increasingly requires more than access to large-scale capacity. It...
Article
Designing Aseptic Fill‑Finish for Today's Biologics: Smart Technologies Meet Annex‑1 Compliance
For sponsors developing high-value biologics, every batch matters. As biologics become more...
Article
Q&A: Getting It Right First Time - The Importance of Early Expression Vector Design
In this interview, Lonza’s Dr. Peter O’Callaghan (Senior Director, Head of Expression System...
Article
Streamlining Stable Cell Line Development from the Start
Developing stable cell lines is one of the most critical, yet time-consuming, steps in recombinant...